Liminal Biosciences Inc. (LMNL): Price and Financial Metrics

Liminal Biosciences Inc. (LMNL): $1.80

-0.13 (-6.74%)

POWR Rating

Component Grades













Add LMNL to Watchlist
Sign Up

Industry: Biotech


of 503

in industry


  • Growth is the dimension where LMNL ranks best; there it ranks ahead of 84.36% of US stocks.
  • The strongest trend for LMNL is in Momentum, which has been heading down over the past 52 weeks.
  • LMNL's current lowest rank is in the Momentum metric (where it is better than 9.5% of US stocks).

LMNL Stock Summary

  • Liminal BioSciences Inc's stock had its IPO on November 18, 2019, making it an older stock than only 3.14% of US equities in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 11.69 for Liminal BioSciences Inc; that's greater than it is for 94.48% of US stocks.
  • Liminal BioSciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -102.05%, greater than the shareholder yield of only 2.22% of stocks in our set.
  • Stocks that are quantitatively similar to LMNL, based on their financial statements, market capitalization, and price volatility, are SNCR, RBBN, IPHA, TVTX, and MX.
  • Visit LMNL's SEC page to see the company's official filings. To visit the company's web site, go to

LMNL Price Target

For more insight on analysts targets of LMNL, see our LMNL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $3.68 Average Broker Recommendation 2.12 (Hold)

LMNL Stock Price Chart Interactive Chart >

Price chart for LMNL

LMNL Price/Volume Stats

Current price $1.80 52-week high $7.07
Prev. close $1.93 52-week low $1.79
Day low $1.79 Volume 198,000
Day high $1.93 Avg. volume 889,970
50-day MA $2.34 Dividend yield N/A
200-day MA $3.85 Market Cap 53.90M

Liminal Biosciences Inc. (LMNL) Company Bio

Liminal Biosciences Inc. operates as a bio-pharmaceutical company. The Company, through its subsidiaries, researches, develops, manufactures, and markets a variety of commercial applications from its core technology. Liminal's applications are used in therapeutics, large-scale drug purification, chemical genomics and proteomics, and drug development.

LMNL Latest News Stream

Event/Time News Detail
Loading, please wait...

LMNL Latest Social Stream

Loading social stream, please wait...

View Full LMNL Social Stream

Latest LMNL News From Around the Web

Below are the latest news stories about Liminal BioSciences Inc that investors may wish to consider to help them evaluate LMNL as an investment opportunity.

Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the remainder of the Company's plasma-derived therapeutics business (the "Second Closing") under the terms of the previously-announced Share Purchase Agreement entered into by the Company and Kedrion S.p.A. ("Kedrion").

Yahoo | October 15, 2021

Liminal BioSciences Announces Closing of Sale of Priority Review Voucher

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that its subsidiary Prometic Biotherapeutics Inc. ("PBT") has closed on the sale of its Priority Review Voucher ("PRV") for USD 105 million.

Yahoo | September 28, 2021

After Plunging 34.5% in 4 Weeks, Here's Why the Trend Might Reverse for Liminal BioSciences Inc. (LMNL)

Liminal BioSciences Inc. (LMNL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | August 23, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Good morning, investor!

William White on InvestorPlace | August 16, 2021

Liminal BioSciences Reports Second Quarter 2021 Financial Results

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today reported its financial results for the second quarter ended June 30, 2021.

Yahoo | August 16, 2021

Read More 'LMNL' Stories Here

LMNL Price Returns

1-mo -28.00%
3-mo -43.22%
6-mo -61.54%
1-year -68.48%
3-year -99.51%
5-year -99.92%
YTD -57.14%
2020 -49.88%
2019 -95.69%
2018 -81.28%
2017 -37.82%
2016 -31.65%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9326 seconds.